spacer
home > pmps > spring 2017 > new thinking
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

New Thinking

When it comes to complacency, Albert Einstein once remarked: “If you always do what you always did, you will always get what you always got.” This very principle applies in healthcare and for today’s seven billion global consumers, who are living longer, have better access to quality care and are demanding more choices, greater convenience and improved outcomes.

It is an evolving paradigm, and delivering sophisticated, high-value pharmaceuticals to emerging markets will require continuous new thinking. The same supply chain issues will continue to pose steady challenges – cost and compliance chief among them – but leveraging cold chain innovations will produce significant gains in years to come.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jan Denecker is responsible for executing UPS’s healthcare strategy in Europe. He joined the company in 2011 as Marketing Manager of Healthcare and led the launch of the department in Europe. In 2014, Jan was appointed Marketing Manager of Belgium and Luxembourg, responsible for business planning, revenue management, marketing and communications in both countries. He holds a Master’s degree in Law from the Université catholique de Louvain, Belgium, and a Master’s degree in Business Administration from the Vlerick School of Management, Belgium.
spacer
Jan Denecker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer

BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement